ARCHIVES

FDA Approves Abraxane For Second-Line Treatment Of Metastatic Breast Cancer

This article is from The Cancer Letter archive.

Vol. 28 No. 1 | January 28, 2005

Download PDF Visit The Full Archive

Related Articles

Sorafenib Targets AML Driven By Mutant FLT3 Gene

February 29, 2008

FDA Proposal To Regulate Tobacco Wins Support Of NCI, Oncology Societies

September 8, 1995

Five Center Core Grants Renewed

February 2, 1979

First Mobil NMR Scanner Goes Into Operation At Temple

June 22, 1984

In Brief: AACR Grants Record Number Of Awards To Young Investigators; Kersey Leads ASBMT

April 24, 1998

Bush Appoints Kripke To President’s Cancer Panel

March 21, 2003